Genedge

Genedge company information, Employees & Contact Information

Explore related pages

Related company profiles:

We’re GENEDGE Alliance (GENEDGE), an economic development entity chartered by the Commonwealth of Virginia in 1992 to deliver customized solutions to solve the operational and business challenges Virginia’s industrial, engineering and manufacturing firms face. We are part of the Manufacturing Extension Partnership (MEP) National Network™, a public-private partnership that empowers small and medium-sized manufacturers to grow and thrive through educational resources, industry connections and best practices. Our number one goal is to make sure Virginia companies have what they need to succeed in Virginia. And for the past 28 years we’ve helped Virginia-based manufacturing, engineering and technology companies find answers and solutions to meet the challenges they face every day. What We Do for Manufacturing and Industry • We deliver customized consulting service to manufacturing, technology and engineering companies throughout Virginia. • Our low-cost, high-value consulting services are designed to help companies innovate, compete, and grow. • Our “Virginia Supply Chain Connector” is a free, online portal connecting manufacturers and suppliers as they work together to build a stronger supply chain.
Looking for a particular Genedge employee's phone or email?

Genedge Questions

News

Smart Systems Create Workforce Solutions - Site Selection Magazine

Smart Systems Create Workforce Solutions Site Selection Magazine

GTC 2024: Nvidia Highlights AI ‘Revolution’ in Drug Discovery, Genomics - Mary Ann Liebert, Inc.

GTC 2024: Nvidia Highlights AI ‘Revolution’ in Drug Discovery, Genomics Mary Ann Liebert, Inc.

GENEDGE and Danville Pittsylvania Chamber of Commerce Launch Next Leadership Development Training Series in Danville - Chatham Star-Tribune

GENEDGE and Danville Pittsylvania Chamber of Commerce Launch Next Leadership Development Training Series in Danville Chatham Star-Tribune

Cytiva Launches Next-Gen Cell Therapy Manufacturing Platform: - Mary Ann Liebert, Inc.

Cytiva Launches Next-Gen Cell Therapy Manufacturing Platform: Mary Ann Liebert, Inc.

StockWatch: Challengers Take Aim at Lilly, Novo Nordisk: - Mary Ann Liebert, Inc.

StockWatch: Challengers Take Aim at Lilly, Novo Nordisk: Mary Ann Liebert, Inc.

eTheRNA Advances mRNA-Based Melanoma Immunotherapy ECI-006 - Mary Ann Liebert, Inc.

eTheRNA Advances mRNA-Based Melanoma Immunotherapy ECI-006 Mary Ann Liebert, Inc.

Seaport Therapeutics Launches with $100M Series A: - Mary Ann Liebert, Inc.

Seaport Therapeutics Launches with $100M Series A: Mary Ann Liebert, Inc.

StockWatch: CDMOs Tumble as Congress Takes Aim at Chinese Biotechs: - Mary Ann Liebert, Inc.

StockWatch: CDMOs Tumble as Congress Takes Aim at Chinese Biotechs: Mary Ann Liebert, Inc.

Mountain Climbing: CAMP4 Aims to Scale the Heights of Disease: - Mary Ann Liebert, Inc.

Mountain Climbing: CAMP4 Aims to Scale the Heights of Disease: Mary Ann Liebert, Inc.

Astellas Takes AIRM Opening New Regenerative Medicine Institute in Massachusetts - Mary Ann Liebert, Inc.

Astellas Takes AIRM Opening New Regenerative Medicine Institute in Massachusetts Mary Ann Liebert, Inc.

Sanofi Extends Deal with CytoReason to License IBD Disease Modeling: - Mary Ann Liebert, Inc.

Sanofi Extends Deal with CytoReason to License IBD Disease Modeling: Mary Ann Liebert, Inc.

Agilent CEO: “We're Not Just a One-Year Wonder!”: - Mary Ann Liebert, Inc.

Agilent CEO: “We're Not Just a One-Year Wonder!”: Mary Ann Liebert, Inc.

StockWatch: Illumina Shares Steady as Icahn Escalates Proxy Fight: - Mary Ann Liebert, Inc.

StockWatch: Illumina Shares Steady as Icahn Escalates Proxy Fight: Mary Ann Liebert, Inc.

With $170M, BioAge Joins Lilly in Oral, Muscle Preserving Obesity Treatment: - Mary Ann Liebert, Inc.

With $170M, BioAge Joins Lilly in Oral, Muscle Preserving Obesity Treatment: Mary Ann Liebert, Inc.

Wide Shot: Jacob Glanville Pursues Broad-Spectrum Vaccines vs. Pandemics: - Mary Ann Liebert, Inc.

Wide Shot: Jacob Glanville Pursues Broad-Spectrum Vaccines vs. Pandemics: Mary Ann Liebert, Inc.

$2B or Not $2B: Fujifilm Diosynth Breaks Ground on NC Cell Culture Facility: - Mary Ann Liebert, Inc.

$2B or Not $2B: Fujifilm Diosynth Breaks Ground on NC Cell Culture Facility: Mary Ann Liebert, Inc.

Sail Biomedicines Emerges from Senda and Laronde to Make Programmable Medicines: - Mary Ann Liebert, Inc.

Sail Biomedicines Emerges from Senda and Laronde to Make Programmable Medicines: Mary Ann Liebert, Inc.

Brain Wave: Neumora Aims Precision Medicine at Neuro Diseases with $500M Launch, Amgen Alliance: - Mary Ann Liebert, Inc.

Brain Wave: Neumora Aims Precision Medicine at Neuro Diseases with $500M Launch, Amgen Alliance: Mary Ann Liebert, Inc.

China Upholds Key CVC CRISPR Patent Licensed through ERS Genomics - Mary Ann Liebert, Inc.

China Upholds Key CVC CRISPR Patent Licensed through ERS Genomics Mary Ann Liebert, Inc.

StockWatch: Biogen Stays Flat Despite Positive 128-Week Aduhelm Data: - Mary Ann Liebert, Inc.

StockWatch: Biogen Stays Flat Despite Positive 128-Week Aduhelm Data: Mary Ann Liebert, Inc.

The Meta(nuclease)verse: Metagenomi Is Developing the Next Generation of Gene-Editing Therapies: - Mary Ann Liebert, Inc.

The Meta(nuclease)verse: Metagenomi Is Developing the Next Generation of Gene-Editing Therapies: Mary Ann Liebert, Inc.

Opiant Eyes Q2 Launch for Pivotal Trial of Opioid Overdose Candidate Aimed at Fentanyl - Mary Ann Liebert, Inc.

Opiant Eyes Q2 Launch for Pivotal Trial of Opioid Overdose Candidate Aimed at Fentanyl Mary Ann Liebert, Inc.

On Your Mark: ALSA Ventures Lifts Early-Stage European Biotechs to Jockey Out of the Gate: - Mary Ann Liebert, Inc.

On Your Mark: ALSA Ventures Lifts Early-Stage European Biotechs to Jockey Out of the Gate: Mary Ann Liebert, Inc.

Rhapsody in B: Tune Therapeutics Presents Data for Hepatitis B Epigenetic Silencer - Mary Ann Liebert, Inc.

Rhapsody in B: Tune Therapeutics Presents Data for Hepatitis B Epigenetic Silencer Mary Ann Liebert, Inc.

Global Blood Therapeutics CEO Defends Price of Sickle-Cell Drug Oxbryta: - Mary Ann Liebert, Inc.

Global Blood Therapeutics CEO Defends Price of Sickle-Cell Drug Oxbryta: Mary Ann Liebert, Inc.

White Space for Drug Discovery: Enlaza Therapeutics Grabs $61 Million to Industrialize Covalent Biologics: - Mary Ann Liebert, Inc.

White Space for Drug Discovery: Enlaza Therapeutics Grabs $61 Million to Industrialize Covalent Biologics: Mary Ann Liebert, Inc.

StockWatch: For Genome Editing, Inflection Points Crowd the Calendar: - Mary Ann Liebert, Inc.

StockWatch: For Genome Editing, Inflection Points Crowd the Calendar: Mary Ann Liebert, Inc.

No-nonsense: Alltrna Touts tRNA Therapeutics to Treat Thousands of Diseases: - Mary Ann Liebert, Inc.

No-nonsense: Alltrna Touts tRNA Therapeutics to Treat Thousands of Diseases: Mary Ann Liebert, Inc.

REGENXBIO and AbbVie Advance Wet AMD Gene Therapy to Phase III: - Mary Ann Liebert, Inc.

REGENXBIO and AbbVie Advance Wet AMD Gene Therapy to Phase III: Mary Ann Liebert, Inc.

Top 15 Best-Selling Drugs of 2019: - Mary Ann Liebert, Inc.

Top 15 Best-Selling Drugs of 2019: Mary Ann Liebert, Inc.

AI Gets Gene Therapy Over the Immunity Hump: - Mary Ann Liebert, Inc.

AI Gets Gene Therapy Over the Immunity Hump: Mary Ann Liebert, Inc.

JMU partners with GENEDGE - James Madison University

JMU partners with GENEDGE James Madison University

Can CRISPR Crack the Code to Treating HIV Infections? - Mary Ann Liebert, Inc.

Can CRISPR Crack the Code to Treating HIV Infections? Mary Ann Liebert, Inc.

StockWatch: Investors Embrace Geron's Comeback Story: - Mary Ann Liebert, Inc.

StockWatch: Investors Embrace Geron's Comeback Story: Mary Ann Liebert, Inc.

Wider Arena: Aristea Pursues Excellence with $123M in Investment: - Mary Ann Liebert, Inc.

Wider Arena: Aristea Pursues Excellence with $123M in Investment: Mary Ann Liebert, Inc.

X Marks the $100 Genome: Illumina Presents New Chemistry, Strong Results: - Mary Ann Liebert, Inc.

X Marks the $100 Genome: Illumina Presents New Chemistry, Strong Results: Mary Ann Liebert, Inc.

Into Orbit: Satellite Bio Raises $110M toward Tissue Therapeutics: - Mary Ann Liebert, Inc.

Into Orbit: Satellite Bio Raises $110M toward Tissue Therapeutics: Mary Ann Liebert, Inc.

Top 15 Best-Selling Drugs of 2018 - Mary Ann Liebert, Inc.

Top 15 Best-Selling Drugs of 2018 Mary Ann Liebert, Inc.

Nucleus RadioPharma: Building CDMO Sites to Ride the Radioligand Therapy Wave: - Mary Ann Liebert, Inc.

Nucleus RadioPharma: Building CDMO Sites to Ride the Radioligand Therapy Wave: Mary Ann Liebert, Inc.

Speak Up to Shape Next-Gen Edge AI - EE Times Europe

Speak Up to Shape Next-Gen Edge AI EE Times Europe

Designer Genes: Synlogic Is Crafting Living Therapeutics Programmed to Treat Disease: - Mary Ann Liebert, Inc.

Designer Genes: Synlogic Is Crafting Living Therapeutics Programmed to Treat Disease: Mary Ann Liebert, Inc.

President Alger shares expertise with GenEdge Alliance - James Madison University

President Alger shares expertise with GenEdge Alliance James Madison University

StockWatch: Moderna Looks to Accelerate Cancer Vaccine: - Mary Ann Liebert, Inc.

StockWatch: Moderna Looks to Accelerate Cancer Vaccine: Mary Ann Liebert, Inc.

SiMa.ai’s Second-Gen Edge AI Chip Goes Multi-Modal - EE Times

SiMa.ai’s Second-Gen Edge AI Chip Goes Multi-Modal EE Times

StockWatch: As Illumina Expands in Multiomics, Analyst Sees Threat to 10x - Genetic Engineering and Biotechnology News

StockWatch: As Illumina Expands in Multiomics, Analyst Sees Threat to 10x Genetic Engineering and Biotechnology News

Empowering Next-Gen Edge AI with MiTAC Platforms Based on Intel’s Arrow Lake-S - Embedded Computing Design

Empowering Next-Gen Edge AI with MiTAC Platforms Based on Intel’s Arrow Lake-S Embedded Computing Design

Carl Icahn States His Case for Change at Illumina on "Close to the Edge" - Genetic Engineering and Biotechnology News

Carl Icahn States His Case for Change at Illumina on "Close to the Edge" Genetic Engineering and Biotechnology News

Top Genedge Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant